ArticleClinical rheumatology2025
Long-term renal outcomes of systemic lupus erythematosus in a Taiwanese population: a single-center retrospective study.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk of chronic kidney disease in newly diagnosed SLE with preserved renal function: a national study.Rheumatology (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the long-term outcome of patients with systemic lupus erythematosus (SLE) who presented with renal involvement in a Taiwanese population.
methodsData of patients diagnosed with SLE at Changhua Christian Hospital Clinical Research Database from January 2010 until December 2021 were retrospectively reviewed. Participants were categorized according to the presence of renal involvement, defined as a high protein-to-creatinine ratio or positive histopathology of kidney biopsy. Incidence rates and risk factors of chronic kidney disease (CKD) and end-stage renal disease (ESRD) were analyzed.
resultsA total of 2184 eligible patients with SLE were enrolled, of which 293 had renal involvement. The risk of CKD/ESRD development was higher among participants with renal involvement compared with those without renal involvement. The median times to development of CKD and ESRD were 2.03 years (IQR: 0.13-6.33) and 7.34 years (IQR: 3.13-10.41), respectively, among renal involvement participants. The cumulative incidence rates of CKD were 46.6%, 54.5%, and 63% at 1, 2, and 5 years after renal involvement, respectively, and those of ESRD were 4%, 7%, and 11%, respectively. In the subgroups of two definitions (PCR- or biopsy-defined renal involvement) for renal involvement, the incidence rate of developing CKD/ESRD was not significantly different between the groups. Multivariate analysis revealed that factors associated with CKD development were renal involvement, age, hypertension, and serositis.
conclusionAmong the Taiwanese population, compared with patients without renal involvement, patients with renal involvement were at a higher risk of developing CKD, and the 5-year incidence rate of ESRD is 11% in this study. Key Points • Among the patients with systemic lupus erythematosus in the Taiwanese population, patients with renal involvement were at a higher risk of developing CKD and ESRD. • The median times-to-development of CKD and ESRD were 2.03 (IQR: 0.13-6.33) years and 7.34 (IQR: 3.13-10.41) years, respectively, among renal involvement participants, whilst the cumulative incidence rates of CKD and ESRD at 5 years after renal involvement were 63% and 11%, respectively. • Subgroup analyses to investigate patients with PCR- and biopsy-defined renal involvement were additionally performed in this study, revealing similar incidence rates of CKD and ESRD in both subgroups.
Indexed as
Identifiers
40892301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.